Combretastatin A4

Product description: Combretastatin A4 is a natural stilbenoid phenol originally isolated from an African shrub, Combretum caffrum. It is a potent inhibitor of tubulin polymerization and displays strong inhibitory activity on tumor cell growth. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. CA4 was shown to impede tumor growth in several cell lines including IMR32 (neuroblastoma), Hs746T (gastric carcinoma), CFPAC-1 (pancreatic carcinoma) and MCF-7 (breast cancer). It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A-4 is the active component of combretastatin A-4 phosphate, a prodrug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. Combretastatin A-4 is therefore a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis.

Alternate Names/Synonyms: 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene; CA4; CRC 87-09; NSC 817373

CAS: 117048-59-6

Lien vers la Fiche Technique